GNT Induction Treatment in Locally Advanced NPC

The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal carcinoma. It aims to answer whether gemcitabine, nimotuzumab and toripalimab as induction treatment show non-inferiority compared to GP induction chemotherapy. Participants will be randomly divided into two induction treatment groups.

Trial Details

NCT ID
NCT06026878
Phase
PHASE3
Sponsor
Air Force Military Medical University, China
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • gemcitabine,nimotuzumab, toripalimab
  • gemcitabine, cisplatin
Locations (sample)
  • Xi'an, Shaanxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Age 18 to 75 years old.
  • Pathologically or cytologically confirmed stage III-IVB nasopharyngeal keratinizing squamous cell carcinoma or non-keratinizing squamous cell carci…
  • Patients suitable for radical radiochemotherapy.
  • ECOG PS score of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →